Quetiapine
- PDF / 169,844 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 90 Downloads / 161 Views
1 S
Rhabdomyolysis: case report A 51-year-old woman developed rhabdomyolysis during treatment with quetiapine for major depression. The woman had been diagnosed with major depression since 24 years along with hypertension. She had been receiving enalapril for the hypertension. On 07 May 2019, she was hospitalised due to relapse of depression (day 1). Between 10 May 2019 and 10 June 2019, she received 10 sessions of modified electroconvulsive therapy. Additionally, the dosage of previously used drugs (sulpiride and amitriptyline) was gradually decreased over the subsequent 5 days. On day 3, she was initiated on sertraline. On day 7, quetiapine was initiated at 25 mg/day [route not stated], which was increased to 50 mg/day on 22 May 2019, and on 5 June 2019, it was further increased to 100 mg/day. On day 44 (19 June 2019), the routine blood investigations revealed a massive elevation in serum levels of creatine kinase (CK), AST, ALT and myoglobin. On the basis of laboratory investigations, a diagnosis of quetiapine-induced rhabdomyolysis was made. The woman’s treatment with quetiapine was therefore stopped on 20 June 2019, and the dose of sertraline was decreased. She was treated with extensive hydration and IV sodium chloride [normal saline] with bicarbonate. After 7 days (on 26 June 2019), she was discharged. Further laboratory investigations revealed normalisation of the serum levels of ALT, CK and AST. Four weeks following the discharge, adjunctive treatment with olanzapine was prescribed, and sertraline was continued. Telephonic follow-up of the patient following 3 months showed no abnormal laboratory test. Li T, et al. Quetiapine-Associated Rhabdomyolysis: A Case Report and Literature Review. Journal of Clinical Psychopharmacology 40: 619-624, No. 6, Nov-Dec 2020. 803515295 Available from: URL: http://doi.org/10.1097/JCP.0000000000001292
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
